Amarantus Biosci Inc (AMBS) 0.0992 $AMBS
Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
GlobeNewswire - Thu Sep 25, 3:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, is pleased to announce the approval of all matters put forth to a vote of the shareholders at the company's Annual Shareholders Meeting.
Amarantus BioScience Holdings, Inc. - "Fundamental Milestones Ahead: Up-Listing from Strength"
ACCESSWIRE - Thu Sep 18, 12:05PM CDT
New York, NY / ACCESSWIRE / September 18, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today provided a program update on its Phase 2b-ready Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia patients ("PD LID"
and adult attention deficit and hyperactivity disorder ("Adult ADHD" . The company expects to initiate its Phase 2b PD LID clinical trial in the fourth quarter of 2014 or early in 2015.
Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Sep 12, 9:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test(R). Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
GlobeNewswire - Wed Sep 10, 12:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6, 2014 at the Westin Boston Waterfront Market in Boston, MA.
Amarantus Announces Positive MANF Ocular Toxicology Data
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications such as Retinitis Pigmentosa. The intravitreal method of administration was chosen because it is the delivery method expected for human application of MANF. The experiments were conducted at a leading ophthalmology contract research laboratory in France.
Market Maker Surveillance Report. AMAT, BAC, SIRI, AAPL, CNC, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:09AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. APPLIED MATERIALS, INC. (NASDAQ:AMAT), BANK OF AMERICA CORPORATION (NYSE:BAC), Sirius XM Radio Inc (NASDAQ:SIRI), Apple Inc (NASDAQ:AAPL), CENTENE CORPORATION (NYSE:CNC), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled to present at the 14 Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for Wednesday, October 1 at 11:45 AM in the Darwin Room. Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.
Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
ACCESSWIRE - Tue Sep 02, 7:26AM CDT
New York, NY / September 2, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
GlobeNewswire - Tue Sep 02, 5:14AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced it has entered into a Master Services Agreement with ICON for global therapeutic and diagnostic clinical development services. Amarantus has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of the company's flagship Alzheimer's blood diagnostic LymPro Test(R) at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY.
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.
Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --
Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
GlobeNewswire - Thu Sep 25, 3:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, is pleased to announce the approval of all matters put forth to a vote of the shareholders at the company's Annual Shareholders Meeting.
Amarantus BioScience Holdings, Inc. - "Fundamental Milestones Ahead: Up-Listing from Strength"
ACCESSWIRE - Thu Sep 18, 12:05PM CDT
New York, NY / ACCESSWIRE / September 18, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today provided a program update on its Phase 2b-ready Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia patients ("PD LID"
and adult attention deficit and hyperactivity disorder ("Adult ADHD" . The company expects to initiate its Phase 2b PD LID clinical trial in the fourth quarter of 2014 or early in 2015. Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Sep 12, 9:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test(R). Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.
Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
GlobeNewswire - Wed Sep 10, 12:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6, 2014 at the Westin Boston Waterfront Market in Boston, MA.
Amarantus Announces Positive MANF Ocular Toxicology Data
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications such as Retinitis Pigmentosa. The intravitreal method of administration was chosen because it is the delivery method expected for human application of MANF. The experiments were conducted at a leading ophthalmology contract research laboratory in France.
Market Maker Surveillance Report. AMAT, BAC, SIRI, AAPL, CNC, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:09AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. APPLIED MATERIALS, INC. (NASDAQ:AMAT), BANK OF AMERICA CORPORATION (NYSE:BAC), Sirius XM Radio Inc (NASDAQ:SIRI), Apple Inc (NASDAQ:AAPL), CENTENE CORPORATION (NYSE:CNC), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled to present at the 14 Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for Wednesday, October 1 at 11:45 AM in the Darwin Room. Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.
Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
ACCESSWIRE - Tue Sep 02, 7:26AM CDT
New York, NY / September 2, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
GlobeNewswire - Tue Sep 02, 5:14AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced it has entered into a Master Services Agreement with ICON for global therapeutic and diagnostic clinical development services. Amarantus has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of the company's flagship Alzheimer's blood diagnostic LymPro Test(R) at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY.
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.
Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.
Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.
Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.
Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.
OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --
